Clinical trials: Malaria, completed
Malaria,Falciparum
To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers
This study is a proof-of-concept, first in human, Phase I, single center study designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers.
- Trial name
- NCT03867331
- Testing
- 5 microgram VLPM01, 15 microgram VLPM01, 30 microgram VLPM01
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Parasitologically Confirmed; Malarial
Artemether-Lumefantrine Clinical Effectiveness Study
In 2009, Papua New Guinea officially adopted artemether-lumefantrine (AL) as new national first-line drug for uncomplicated malaria.
- Trial name
- NCT01599000
- Testing
- Artemether-lumefantrine combination
- Where
- Papua New Guinea
- Volunteers
- 159 people
- Sponsor
- Papua New Guinea Institute of Medical Research
Uncomplicated Knowlesi Malaria
P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine
Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however there are no current WHO treatment guidelines for this infection.
- Trial name
- CAN KNOW (NCT02001012)
- Testing
- Artemether-lumefantrine combination, Chloroquine
- Where
- 3 sites in Malaysia
- Volunteers
- 123 people
- Sponsor
- Menzies School of Health Research
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.
- Trial name
- NCT01323972
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
- Where
- 2 sites in Nigeria
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
The Democratic Republic of the Congo (DRC) is among the countries most affected by malaria in Sub-Saharan Africa. Condidering its size and the geographic position, the DRC is meant to play a major role in the malaria control in…
- Trial name
- TETRDC2016 (NCT02940756)
- Testing
- artesunate-amodiaquine, artemether-lumefantrine, Dihydroartemisinine-piperaquine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,615 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Malaria
A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania
Pregnant women are vulnerable to malaria, with significant implications both for their health and for the pregnancy. Sulfadoxine-pyrimethamine (SP) is currently the first line drug for the treatment of malaria in pregnancy in…
- Trial name
- NCT00146731
- Testing
- SP, SP + amodiaquine, AQ + artesunate
- Where
- Tanzania
- Volunteers
- 310 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Pregnancy
A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda
SUMMARY Background: Malaria is the leading cause of morbidity and mortality among pregnant women in Uganda. Although effective tools for prevention and control of malaria exist, their delivery presents a problem.
- Conditions
- Malaria, Pregnancy, Anemia
- Trial name
- NCT00118027
- Testing
- sulphadoxine-pyrimethamine intermittent preventive treatment
- Where
- Uganda
- Volunteers
- 2,150 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Prevalence Survey of Antimalarial Drug Resistance Markers
Study is cross-sectional and observational with one-time dried-blood spot sample collection from persons with laboratory-confirmed uncomplicated Plasmodium falciparum malaria (mixed or monoinfection).
- Trial name
- NCT03217851
- Testing
- Blood Collection, Dried Blood Spot
- Where
- Thailand
- Volunteers
- 4,000 people
- Sponsor
- University of Oxford
Pregnancy; HIV; Malaria
Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)
2.3.3 Short technical protocol summary Background: Pregnant women represent a vulnerable population for malaria. HIV-infected women are particularly at risk.
- Trial name
- IMPROVE-2 (NCT04158713)
- Testing
- Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
- Where
- Kenya
- Volunteers
- 898 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Malaria, Plasmodium Falciparum Malaria
Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults
This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P.
- Trial name
- NCT02132299
- Testing
- PfSPZ Vaccine, PfSPZ Challenge
- Where
- Tanzania
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area
Infants in malaria-endemic regions of Africa are an important target for vaccination against malaria in view of the enormous disease burden of malaria in this population.
- Trial name
- NCT01450293
- Testing
- AdCh63 ME-TRAP, MVA ME-TRAP
- Where
- The Gambia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Plasmodium Falciparum
A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania
This will be a single-centre, open label trial to determine the safety and feasibility of CHMI model using Plasmodium falciparum-infected cryopreserved erythrocytes administered to healthy Tanzanian adults with varying prior…
- Trial name
- NCT04788862
- Testing
- P. falciparum infected erythrocytes
- Where
- Tanzania
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults
MALARIA-092 (NCT03162614) study was designed to evaluate the efficacy, immunogenicity and safety of various dose schedules and formulations of GSK Biologicals' candidate malaria vaccine (RTS,S/AS01E) in healthy malaria-naïve…
- Trial name
- NCT03824236
- Testing
- RTS,S/AS01E (SB257049)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
P. Falciparum Malaria
Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites
In the EHMI-8 study (CMO 2006/207) the investigators induced sterile protection against P. falciparum challenge in healthy Dutch volunteers by repeated exposure to infected mosquitoes whilst under chloroquine prophylaxis.
- Trial name
- NCT00757887
- Testing
- Exposure to 5 P. falciparum infected mosquitoes
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso
This is a two-arm study aiming at recruiting 150 patients to assess the efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) in patients with a microscopy positive diagnosis of malaria in Nanoro, Burkina…
- Trial name
- NCT01697787
- Testing
- Amodiaquine-Artesunate, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 150 people
- Sponsor
- Centre Muraz
Plasmodium Falciparum Malaria, Vaccines
Experimental Vaccine for Plasmodium Falciparum Malaria
This study will evaluate the safety of two experimental malaria vaccines in healthy volunteers and examine their immune response to them.
- Trial name
- NCT00340431
- Testing
- MSP1(42)-FVO & MSP1(42)-3D7
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Vivax
Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru. The implementation package includes the following interventions: A revised vivax treatment algorithm…
- Trial name
- NCT05361486
- Testing
- Tafenoquine (TQ)
- Where
- Peru
- Volunteers
- 187 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield
The investigators are proposing a new malaria control strategy to reach the group of garimpeiros not reached by the usual actions of the health services.
- Trial name
- CUREMA (NCT05540470)
- Testing
- PART, Malakit, CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS
- Where
- 2 sites in Brazil, Suriname
- Volunteers
- 1,991 people
- Sponsor
- Centre Hospitalier de Cayenne
Malaria
Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali
Background: Malaria is a disease that affects many people in the country of Mali and other parts of Africa. It is caused by germs that are spread by mosquito bites.
- Trial name
- NCT02659566
- Where
- Mali
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.